Biomarkers in Gastrointestinal Cancer: Evidence-Based Treatment in the Precision Medicine Era

Biomarkers in Gastrointestinal Cancer: Evidence-Based Treatment in the Precision Medicine Era

Friday, January 21, 2022
Webinar -- 6:30 PM PT
http://www.clinicaloptions.com/GIBiomarkersSF2022Join1

Agenda

  • Histology-Agnostic Biomarkers in GI Malignancies
  • Biomarker-Driven Treatment of Advanced Colorectal Cancer
  • Biomarker-Driven Treatment of Pancreatic and Hepatobiliary Cancer
  • Biomarker-Driven Treatment: Gastric, Esophageal, and Gastroesophageal Junction Cancers
  • Live Audience Question and Answer Session

Faculty

Program Director
John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Faculty
Manish A. Shah, MD

Bartlett Family Professor of Gastrointestinal Oncology
Chief, 
Solid Tumor Services
Director, Gastrointestinal Oncology Program
Co-Director, Center for Advanced Digestive Care
Weill Cornell Medical College
NewYork-Presbyterian Hospital
New York, New York

Faculty
Rachna Shroff, MD

Assistant Professor of Medicine
Chief
, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Goal Statement

The goal of this program is to improve the knowledge and competence of learners in biomarker testing to guide selection of individualized treatments for patients with gastrointestinal malignancies.

Target Audience

This educational program is intended for medical oncologists, and other healthcare professional who treat patients with gastrointestinal cancers.

Learning Objectives

  • Apply the available data and expert recommendations to order and accurately interpret molecular profiling for patients with GI malignancies to guide treatment selection
  • Plan therapeutic strategies for patients with GI malignancies based on predictive biomarker assessment
  • Counsel patients about how the molecular profile will guide therapy decisions and potential need for additional biopsy
  • Appraise ongoing clinical trials for novel biomarker-driven treatment strategies in GI malignancies for patient counsel and potential enrollment

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.